Related Experiment Video
Updated: Mar 31, 2026

06:26
Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
Published on: May 16, 2021
5.7K
Identification of KLHL12 Ligands Using Fragment-Based Methods.
Alex G Waterson1,2, Anish Vadukoot3, Somnath Jana4
1Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Journal of Medicinal Chemistry
|March 30, 2026
Summary
Researchers identified new small molecules that bind to the KLHL12 E3 ligase. This discovery expands the tools for targeted protein degradation, potentially leading to new cancer therapies by selectively degrading tumor proteins.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- Targeted protein degradation utilizes E3 ligases to direct proteins for destruction.
- Current methods are limited by the small number of well-characterized E3 ligases.
- KLHL12 is an E3 ligase overexpressed in cancers, presenting a potential therapeutic target.
Purpose of the Study:
- To identify novel ligands for the KLHL12 E3 ligase.
- To expand the toolkit of E3 ligases available for targeted protein degradation.
- To develop small molecules for potential cancer therapy.
Main Methods:
- Nuclear Magnetic Resonance (NMR)-based screening to identify KLHL12-binding fragments.
- X-ray crystallography to determine the structure of fragment-KLHL12 complexes.
- Structure-guided optimization of initial fragment hits.
Main Results:
- Identified fragments that bind to KLHL12.
- Obtained X-ray crystal structures of KLHL12-fragment complexes.
- Developed the first small molecules with submicromolar affinity for KLHL12.
Conclusions:
- KLHL12 can be targeted by small molecules.
- These novel compounds are a foundation for developing Proteolysis Targeting Chimeras (PROTACs).
- Targeted degradation using KLHL12 ligands may offer selective cancer treatment strategies.

